JNJCL Stock Overview
Researches, develops, manufactures, and sells various products in the healthcare field worldwide.
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 2/6 |
| Past Performance | 4/6 |
| Financial Health | 6/6 |
| Dividends | 4/6 |
Johnson & Johnson Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$155,930.00 |
| 52 Week High | US$156,750.00 |
| 52 Week Low | US$123,870.00 |
| Beta | 0.55 |
| 1 Month Change | 0% |
| 3 Month Change | 0% |
| 1 Year Change | -1.30% |
| 3 Year Change | 29.01% |
| 5 Year Change | n/a |
| Change since IPO | 29.01% |
Recent News & Updates
Recent updates
Shareholder Returns
| JNJCL | CL Pharmaceuticals | CL Market | |
|---|---|---|---|
| 7D | 0% | 0% | 0% |
| 1Y | -1.3% | 0% | 0% |
Return vs Industry: JNJCL exceeded the CL Pharmaceuticals industry which returned -19% over the past year.
Return vs Market: JNJCL underperformed the CL Market which returned 18.7% over the past year.
Price Volatility
| JNJCL volatility | |
|---|---|
| JNJCL Average Weekly Movement | 0% |
| Pharmaceuticals Industry Average Movement | 0% |
| Market Average Movement | 0% |
| 10% most volatile stocks in CL Market | 0% |
| 10% least volatile stocks in CL Market | 0% |
Stable Share Price: JNJCL has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine JNJCL's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1886 | 131,900 | Joaquin Duato | www.jnj.com |
Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company’s Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use. Its MedTech segment provides Interventional Solutions, including electrophysiology products to treat heart rhythm disorders; the heart recovery portfolio, which includes technologies to treat severe coronary artery disease requiring high-risk PCI or AMI cardiogenic shock; and neurovascular care that treats hemorrhagic and ischemic stroke.
Johnson & Johnson Fundamentals Summary
| JNJCL fundamental statistics | |
|---|---|
| Market cap | CL$315.85t |
| Earnings (TTM) | CL$15.51t |
| Revenue (TTM) | CL$77.82t |
20.4x
P/E Ratio4.1x
P/S RatioIs JNJCL overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| JNJCL income statement (TTM) | |
|---|---|
| Revenue | US$85.65b |
| Cost of Revenue | US$26.26b |
| Gross Profit | US$59.39b |
| Other Expenses | US$42.32b |
| Earnings | US$17.07b |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
Jul 17, 2024
| Earnings per share (EPS) | 7.09 |
| Gross Margin | 69.34% |
| Net Profit Margin | 19.93% |
| Debt/Equity Ratio | 48.0% |
How did JNJCL perform over the long term?
See historical performance and comparison